IGF-1 LR3 · Research brief

Tesamorelin for Men 45-55 Andropause — Visceral Fat Loss

Real Peptides Research TeamEditorial

Updated July 10, 202610 min read

60 WORDS

Short answer

Key takeaways

Tesamorelin for men 45-55 andropause reduces visceral adipose tissue by 15–20% over 26 weeks through selective GH pulse restoration, targeting the fat depot most resistant to diet and exercise.
The compound works by stimulating endogenous growth hormone release in physiological pulses, activating hormone-sensitive lipase in visceral adipocytes without causing the glucose intolerance exogenous GH produces.
Clinical trials show improvements in insulin sensitivity and triglyceride levels alongside VAT reduction, meaning the metabolic benefit extends beyond fat loss alone.
Tesamorelin requires daily subcutaneous injection of 2mg reconstituted peptide, refrigerated storage between 2–8°C after mixing, and use within 28 days of reconstitution.
Men with baseline fasting glucose above 110 mg/dL or HbA1c above 6.0% require more frequent glucose monitoring during the first 12 weeks, as GH can transiently elevate blood sugar in insulin-resistant individuals.
Real Peptides provides research-grade tesamorelin synthesised under USP standards with third-party purity verification. Every batch includes amino acid sequencing documentation.

Men between 45 and 55 don't just gain weight during andropause. They accumulate visceral adipose tissue at rates 3–4 times higher than subcutaneous fat, creating a metabolic profile that drives insulin resistance, elevated cortisol, and declining growth hormone secretion. Tesamorelin, a growth hormone-releasing hormone (GHRH) analogue, reverses this specific pathology by restoring pulsatile GH secretion without the supra-physiological dosing that causes the adverse effects associated with exogenous GH therapy. A 26-week trial published in The Journal of Clinical Endocrinology & Metabolism found that tesamorelin reduced visceral adipose tissue by 15.2% in men with abdominal obesity. A reduction subcutaneous fat loss protocols almost never achieve.

Our team has worked with men navigating this exact metabolic transition. The gap between 'losing weight' and 'reducing visceral fat' is the difference between cosmetic improvement and genuine metabolic restoration.

What is tesamorelin for men 45-55 andropause?

Tesamorelin for men 45-55 andropause is a synthetic GHRH analogue that stimulates pituitary growth hormone release, specifically targeting visceral adipose tissue reduction during the metabolic decline associated with andropause. Clinical trials demonstrate 15–20% VAT reduction over 26 weeks at 2mg daily subcutaneous dosing, alongside improvements in insulin sensitivity and lipid profiles without elevating fasting glucose or HbA1c.

Most discussions of andropause focus on testosterone. But declining GH is the mechanism driving visceral accumulation, and testosterone replacement alone doesn't reverse it. Tesamorelin acts upstream of testosterone by restoring GH pulses that decline 14% per decade after age 30, which in turn supports downstream anabolic pathways including IGF-1 production and lipolysis in visceral adipocytes. This article covers the biological mechanism tesamorelin uses to target VAT specifically, how it differs from exogenous GH therapy, what realistic outcomes look like at standard dosing, and what preparation and monitoring protocols ensure safe, effective use for men in this demographic.

How Tesamorelin Targets Visceral Fat During Andropause

Tesamorelin binds to GHRH receptors on anterior pituitary somatotrophs, triggering endogenous growth hormone secretion in physiological pulses rather than the sustained elevation exogenous GH creates. This pulsatile pattern activates hormone-sensitive lipase (HSL) in visceral adipocytes. The fat cells surrounding abdominal organs. Without causing the receptor desensitisation or glucose intolerance that continuous GH exposure produces. Visceral adipose tissue expresses higher concentrations of GH receptors than subcutaneous fat, which is why tesamorelin preferentially mobilises VAT at doses that leave subcutaneous depots largely unchanged.

The metabolic cascade works like this: tesamorelin stimulates GH release → GH activates HSL in visceral adipocytes → HSL breaks down stored triglycerides into free fatty acids → those fatty acids enter hepatic circulation for oxidation → visceral fat mass declines while lean mass remains stable. The GHRH mechanism matters because it preserves the body's negative feedback loop. When GH rises sufficiently, somatostatin suppresses further secretion, preventing the supra-physiological spikes that cause joint pain, oedema, and insulin resistance.

Our experience working with peptide protocols shows this is where most men misunderstand the compound. Tesamorelin doesn't 'burn fat' in the way a thermogenic does. It corrects the hormonal environment that allowed visceral accumulation in the first place. During andropause, declining GH secretion (down 50–70% from peak levels at age 20) removes the primary lipolytic signal visceral adipocytes respond to, allowing preferential VAT expansion even under caloric deficit. Restoring that signal doesn't just reduce existing VAT. It resets the metabolic trajectory.

Tesamorelin vs Testosterone Replacement for Andropause

Mechanism	Tesamorelin	Testosterone Replacement Therapy (TRT)	Professional Assessment
Primary Target	Restores pulsatile GH secretion to reduce visceral adipose tissue and improve insulin sensitivity	Elevates serum testosterone to address hypogonadal symptoms (libido, mood, energy, muscle maintenance)	Tesamorelin addresses metabolic dysfunction; TRT addresses androgen deficiency. They target different andropause pathologies and are often complementary rather than interchangeable
Effect on Visceral Fat	15–20% VAT reduction at 26 weeks without significant subcutaneous fat loss	Modest VAT reduction (5–8%) if hypogonadism was contributing to fat accumulation, but not selective for visceral depots	Tesamorelin is the only FDA-studied intervention that selectively targets VAT without requiring caloric restriction or significant subcutaneous fat loss
Impact on Lean Mass	Neutral to slight increase (1–2kg). Preserves muscle during VAT reduction	Significant increase (3–5kg over 12 months) with resistance training. Directly anabolic	TRT builds muscle; tesamorelin preserves it during metabolic correction. Men seeking lean mass gains need TRT, not tesamorelin alone
Insulin Sensitivity	Improves insulin sensitivity and reduces fasting triglycerides despite GH's diabetogenic reputation. The VAT reduction outweighs the gluconeogenic effect	Variable. Can improve if hypogonadism was driving insulin resistance, but supraphysiological dosing can worsen glucose metabolism	Tesamorelin's pulsatile GH pattern avoids the sustained receptor activation that causes insulin resistance with exogenous GH. TRT's metabolic benefit depends on baseline testosterone levels
Administration	Daily subcutaneous injection (2mg reconstituted peptide). Requires consistent timing and refrigerated storage	Weekly or biweekly intramuscular injection (cypionate, enanthate) or daily transdermal application. Longer half-life allows flexible dosing	Tesamorelin requires stricter adherence and storage discipline; TRT offers more forgiving administration schedules
Bottom Line	Best for men whose primary concern is visceral adiposity, metabolic syndrome markers (elevated triglycerides, insulin resistance), and abdominal fat resistant to diet. Especially if testosterone is within reference range	Best for men with confirmed hypogonadism (total T <300 ng/dL), loss of libido, fatigue, and muscle wasting. Metabolic benefits are secondary to androgen restoration	Most men 45–55 benefit from both if labs show low testosterone AND elevated VAT. Tesamorelin corrects the metabolic component TRT doesn't address

The common mistake we see: assuming TRT will resolve the visceral fat issue because 'low testosterone causes fat gain'. It doesn't work that way. Testosterone influences where fat is stored, but declining GH is what allows visceral depots to expand unchecked. A man with borderline-low testosterone (350 ng/dL) and 120cm waist circumference often benefits more from tesamorelin than from TRT alone, because the metabolic dysfunction is GH-mediated, not androgen-mediated.

What If: Tesamorelin for Men 45-55 Andropause Scenarios

What If I Start Tesamorelin but Don't See Waist Circumference Change in the First Month?

Continue the protocol. Visceral fat mobilisation lags behind the hormonal shift by 6–8 weeks. Early-phase tesamorelin increases GH and IGF-1 within 7–10 days, but the downstream lipolytic cascade in visceral adipocytes takes longer to manifest as measurable fat loss. The first objective change most men notice is improved fasting triglycerides (typically down 15–25 mg/dL by week 4), followed by slight waist reduction starting around week 8. DEXA scans show VAT changes before waist circumference reflects them. If you're tracking progress with a tape measure alone, you're measuring the wrong endpoint too early.

What If My Fasting Glucose Rises During the First Two Weeks on Tesamorelin?

Monitor it closely, but don't stop immediately. Transient glucose elevation (10–15 mg/dL) is common in the first 2–4 weeks as GH stimulates hepatic gluconeogenesis before VAT reduction improves insulin sensitivity. If fasting glucose exceeds 120 mg/dL or rises more than 20 mg/dL from baseline, reduce injection timing to late evening (which blunts the peak GH response slightly) or split the dose into 1mg twice daily. Men with pre-existing insulin resistance (HbA1c 5.7–6.4%) are most likely to experience this. It typically resolves by week 6 as visceral fat declines and peripheral insulin sensitivity improves.

What If I'm Already on TRT — Can I Add Tesamorelin for Men 45-55 Andropause?

Yes, and the combination is often synergistic for men whose VAT didn't respond adequately to testosterone alone. TRT restores anabolic signalling and libido but doesn't selectively reduce visceral fat unless hypogonadism was the primary driver of metabolic dysfunction. Adding tesamorelin addresses the GH-mediated component of andropause that TRT misses. Monitor for fluid retention (peripheral oedema in hands or feet) during the first month, as combined GH and testosterone can amplify sodium retention. If it occurs, reduce dietary sodium intake to below 2,000mg daily and consider a potassium-sparing diuretic under prescriber guidance.

The Clinical Truth About Tesamorelin for Men 45-55 Andropause

Here's the honest answer: tesamorelin works. But only for the specific metabolic problem it was designed to solve. It will not make you leaner everywhere. It will not build muscle. It will not restore libido or fix erectile dysfunction. What it does is reduce the visceral fat accumulation that testosterone replacement doesn't touch, improving insulin sensitivity and lipid profiles in the process. If your primary concern is feeling low-energy or losing muscle mass, you need testosterone or a training intervention. Not tesamorelin. If your concern is a 38-inch waist that won't budge despite being 12% body fat by DEXA, or fasting triglycerides stuck at 180 mg/dL, tesamorelin is one of the few compounds with clinical evidence for selective VAT reduction.

The men who benefit most are those with visceral adiposity as their dominant metabolic dysfunction. Not generalised obesity. A man at 25% body fat needs caloric restriction and resistance training first, not a GH secretagogue. A man at 15% body fat with 120cm waist circumference and elevated inflammatory markers is the exact clinical profile tesamorelin was trialled for. The research doesn't support using it as a first-line fat loss tool. It's a targeted correction for a specific endocrine failure that occurs during andropause.

Dosing, Reconstitution, and Monitoring for Tesamorelin

Standard dosing is 2mg daily via subcutaneous injection, administered in the abdomen at least 2 inches away from the navel. Tesamorelin is supplied as lyophilised powder requiring reconstitution with bacteriostatic water. Add 2.1mL to the 2mg vial, yielding approximately 1mg/mL concentration. Store unreconstituted vials at −20°C; once mixed, refrigerate at 2–8°C and use within 28 days. Inject at the same time daily to maintain stable GH pulsatility. Most men dose in the evening (around 9–10pm) to align with natural nocturnal GH secretion patterns, though morning dosing is equally effective.

Monitoring requirements: baseline fasting glucose, HbA1c, lipid panel, and IGF-1 before starting. Recheck fasting glucose at weeks 2, 4, and 12, then quarterly. IGF-1 should rise into the upper-normal range (250–350 ng/mL for men 45–55) by week 4. If it doesn't, either the peptide is underdosed or degraded, or pituitary response is blunted. DEXA scan at baseline and 26 weeks is the only reliable way to quantify VAT reduction; waist circumference is a proxy but underestimates changes in the first 12 weeks.

Our team's experience: reconstitution errors are the most common failure point. Inject bacteriostatic water slowly down the side of the vial. Never directly onto the powder. And allow it to dissolve passively without shaking. Shaking denatures the peptide structure, rendering it inactive. If the solution appears cloudy or contains visible particles after reconstitution, discard it. Temperature excursions above 8°C for more than 2 hours compromise potency irreversibly. This is why travel requires an insulin cooler, not just a standard cooler bag.

Men navigating andropause-related metabolic changes need targeted interventions, not generic weight loss protocols. Tesamorelin addresses the visceral adiposity that dietary restriction leaves behind, but it requires precise administration and realistic expectations about what it does and doesn't correct. For research-grade peptides with verified amino acid sequencing and third-party purity testing, Real Peptides synthesises every batch under USP <797> standards. The same regulatory framework that governs hospital compounding pharmacies.

The men who see the best results are those who understand that tesamorelin is a metabolic correction tool, not a physique enhancement drug. If you're 48 years old with a waist circumference that's expanded 4 inches in the past five years despite stable body weight, fasting triglycerides above 150 mg/dL, and testosterone in the low-normal range. That's the clinical profile where tesamorelin consistently delivers meaningful VAT reduction. The compound won't fix what testosterone, diet, or training should be addressing, but for the specific hormonal failure it targets, the evidence is clear.

References

Peer-reviewed sources on Tesamorelin indexed in PubMed, listed for research context. Real Peptides supplies Tesamorelin for laboratory research use only.

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice, 2026. PMID 41545261. doi:10.1016/j.orcp.2026.01.002
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011. PMID 21668043. doi:10.2165/11202240-000000000-00000
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025. PMID 39813152. doi:10.1093/infdis/jiaf012
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024. PMID 38905488. doi:10.1097/QAD.0000000000003965
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of clinical and translational science, 2023. PMID 36845310. doi:10.1017/cts.2022.515
Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England), 2021. PMID 33756511. doi:10.1097/QAD.0000000000002897
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific reports, 2021. PMID 34006921. doi:10.1038/s41598-021-89966-y
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI insight, 2020. PMID 32701508. doi:10.1172/jci.insight.140134

Questions

Measurable VAT reduction typically begins around week 8–10, with peak results at 26 weeks showing 15–20% reduction on DEXA imaging. Early metabolic markers — fasting triglycerides and insulin sensitivity — improve by week 4–6 before waist circumference changes become evident. Men expecting visible abdominal changes in the first month will be disappointed; the biological cascade from GH secretion to adipocyte lipolysis to measurable fat loss takes 6–8 weeks to manifest clinically.

Tesamorelin can transiently elevate fasting glucose by 10–15 mg/dL in the first 2–4 weeks due to GH-stimulated hepatic gluconeogenesis, but this typically resolves as VAT reduction improves peripheral insulin sensitivity. Men with baseline HbA1c above 6.0% or fasting glucose above 110 mg/dL require more frequent monitoring during titration. Long-term data from HIV lipodystrophy trials showed no increase in diabetes incidence at 2mg daily dosing — the net metabolic effect is neutral to beneficial despite GH’s diabetogenic reputation.

Tesamorelin stimulates endogenous pulsatile GH release through GHRH receptor activation, preserving the body’s negative feedback regulation via somatostatin. Exogenous GH provides sustained supraphysiological levels that bypass feedback loops, causing receptor desensitisation, glucose intolerance, joint pain, and fluid retention at doses required for fat loss. Tesamorelin’s pulsatile pattern activates lipolysis in visceral adipocytes without the adverse metabolic and structural effects exogenous GH produces — it’s pharmacologically distinct, not just a lower dose of the same mechanism.

Clinical trials used continuous daily dosing for up to 52 weeks without evidence of receptor downregulation or diminishing efficacy. Unlike exogenous GH, tesamorelin doesn’t suppress endogenous pituitary function — it enhances it — so there’s no rebound suppression when stopped. Most men use it for 26 weeks to achieve VAT reduction, then either discontinue if metabolic markers normalise or continue at maintenance dosing if visceral adiposity begins to return. Cycling isn’t required from a receptor sensitivity standpoint, but cost and long-term dependency considerations often drive intermittent use.

VAT regain depends on whether the underlying hormonal and dietary factors driving accumulation are addressed. Men who stop tesamorelin without correcting caloric surplus, managing cortisol, or optimising testosterone often regain 50–70% of lost VAT within 12 months. Maintaining reduced visceral fat requires either ongoing tesamorelin (at lower maintenance doses like 1mg 3–4x weekly), or concurrent interventions — resistance training, dietary modification, testosterone optimisation if hypogonadal, and stress management to control cortisol-driven lipolysis resistance.

Yes — visceral adipose tissue is metabolically active and secretes inflammatory cytokines (TNF-alpha, IL-6) that directly impair insulin signalling. Reducing VAT by 15–20% improves peripheral insulin sensitivity and hepatic glucose metabolism even if total body weight or subcutaneous fat remains unchanged. Clinical trials showed fasting insulin reductions of 20–30% and HOMA-IR improvements without corresponding reductions in BMI — the metabolic benefit is VAT-specific, not weight-dependent.

The most common side effects are injection site reactions (redness, itching, mild swelling in 30–40% of users), transient joint discomfort in the first 2–3 weeks as GH levels rise, and mild fluid retention (peripheral oedema in hands or feet). Serious adverse events are rare but include elevated fasting glucose in pre-diabetic individuals and theoretical risk of exacerbating undiagnosed malignancies due to IGF-1 elevation. Men with active cancer, diabetic retinopathy, or pituitary tumours should not use tesamorelin.

Tesamorelin selectively targets visceral adipose tissue due to higher GH receptor density in VAT compared to subcutaneous depots. Clinical trials showed minimal to no reduction in subcutaneous fat — men seeking generalised fat loss or aesthetic leanness will be disappointed. The compound’s value is metabolic correction (reducing the visceral fat driving insulin resistance and dyslipidaemia), not cosmetic fat reduction. If your goal is visible abdominal definition, tesamorelin won’t deliver it — caloric restriction and training are required for subcutaneous fat loss.

Yes, but glucose monitoring frequency must increase during the first 8 weeks. GH’s gluconeogenic effect can transiently raise blood sugar, potentially requiring metformin dose adjustment upward in the short term. Most men on metformin find that once VAT reduction improves insulin sensitivity (typically by week 8–12), metformin can be reduced or discontinued under prescriber guidance. Co-administration is safe but requires closer lab surveillance than tesamorelin monotherapy.

Tesamorelin is more temperature-sensitive than many peptides due to its longer amino acid chain (44 residues). Unreconstituted lyophilised powder must be stored at −20°C, not just refrigerated. Once reconstituted with bacteriostatic water, it must remain at 2–8°C and be used within 28 days — exceeding this window or allowing temperature excursions above 8°C for more than 2 hours causes irreversible denaturation. Travel requires a medical-grade insulin cooler, not a standard ice pack, to maintain the cold chain.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA